Current treatments for methicillin-resistant Staphylococcus aureus (MRSA) infections require intravenously delivered vancomycin; however, systemically delivered vancomycin has its problems. To determine the feasibility and safety of locally delivering vancomycin hydrochloride (~25 mg/Kg) to the medullary canal of long bones, we conducted a pharmacokinetics study using a rat tibia model. We found that administering the vancomycin intraosseously resulted in very low concentrations of vancomycin in the blood plasma and the muscle surrounding the tibia, reducing the risk for systemic toxicity, which is often seen with traditional intravenous administration of vancomycin. Additionally, we were able to inhibit the development of osteomyelitis in the tibia if the treatment was administered locally at the same time as a bacterial inoculum (i.e., Log10 7.82 CFU/mL or 6.62x107 CFU/mL), when compared to an untreated group. These findings suggest that local intramedullary vancomycin delivery can achieve sufficiently high local concentrations to prevent development of osteomyelitis while minimizing systemic toxicity.

Last modified

• 04/16/2024

Creator

• Loc-Carrillo, Catherine

Contributors

• Wu, Sijia
• Fernandez, Sheena
• Burr, Michael
• Fredricksen, Hunter
• Canden, Ahranee
• Hoerger, Kelly
• Churchill, John
• Wang, Caroline
• Agarwal, Jay

Subject

• Infectious Diseases

Language

• English

Identifier

• https://doi.org/10.7278/S5W0942B

Keyword

• pharmacokinetics
• tibia
• infections
• systematic toxicity
• bone
• antibiotics
• rat
• osteomyelitis
• vancomycin

Date created

• 2013-05-01 to 2015-01-30

Location

• Salt Lake City, Utah, United States

Related url

•  https://doi.org/10.1371/journal.pone.0160187

Resource type

• Dataset

Source

• MeSH

License

• CC BY NC - Allows others to use and share your data non-commercially and with attribution.